INMB logo

INmune Bio (INMB) Company Overview

Profile

Full Name:

INmune Bio, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 4, 2019

Indexes:

Not included

Description:

INmune Bio is a biotechnology company focused on developing treatments for neurodegenerative diseases and cancer. They use innovative approaches to enhance the immune system's ability to fight diseases, aiming to improve patient outcomes and quality of life through advanced therapies.

Key Details

Price

$7.84

Annual Revenue

$155.00 K(-58.56% YoY)

Annual EPS

-$1.67(-9.87% YoY)

Annual ROE

-61.09%

Beta

1.96

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Oct 31, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 13, 25 Maxim Group
Buy
Feb 11, 25 Scotiabank
Sector Outperform
Jun 1, 23 Baird
Outperform
May 24, 22 BTIG
Buy
May 24, 22 B. Riley Securities
Neutral
Jan 24, 22 B. Riley Securities
Buy
Apr 21, 21 B. Riley Securities
Buy
Apr 21, 21 B. Riley FBR
Buy
Nov 25, 20 Roth Capital
Buy
Nov 25, 20 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for INmune Bio?
  • Does INmune Bio pay dividends?
  • What sector is INmune Bio in?
  • What industry is INmune Bio in?
  • What country is INmune Bio based in?
  • When did INmune Bio go public?
  • Is INmune Bio in the S&P 500?
  • Is INmune Bio in the NASDAQ 100?
  • Is INmune Bio in the Dow Jones?
  • When was INmune Bio's last earnings report?
  • When does INmune Bio report earnings?
  • Should I buy INmune Bio stock now?

What is the ticker symbol for INmune Bio?

The ticker symbol for INmune Bio is NASDAQ:INMB

Does INmune Bio pay dividends?

No, INmune Bio does not pay dividends

What sector is INmune Bio in?

INmune Bio is in the Healthcare sector

What industry is INmune Bio in?

INmune Bio is in the Biotechnology industry

What country is INmune Bio based in?

INmune Bio is headquartered in United States

When did INmune Bio go public?

INmune Bio's initial public offering (IPO) was on February 4, 2019

Is INmune Bio in the S&P 500?

No, INmune Bio is not included in the S&P 500 index

Is INmune Bio in the NASDAQ 100?

No, INmune Bio is not included in the NASDAQ 100 index

Is INmune Bio in the Dow Jones?

No, INmune Bio is not included in the Dow Jones index

When was INmune Bio's last earnings report?

INmune Bio's most recent earnings report was on Oct 31, 2024

When does INmune Bio report earnings?

The next expected earnings date for INmune Bio is Mar 28, 2025

Should I buy INmune Bio stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions